IQVIA Holdings Inc. (IQV) shares surged 5.63% in pre-market trading on Thursday as the healthcare data analytics provider reported better-than-expected fourth quarter results, driven by robust demand for its technology and analytics solutions.

For the quarter ended December 31, 2024, IQVIA posted revenue of $3.96 billion, surpassing analysts' estimates of $3.93 billion. Adjusted earnings per share came in at $3.12, beating the consensus forecast of $3.11.

The company's Technology & Analytics Solutions segment continued to be a standout performer, benefiting from increased spending by pharmaceutical and consumer healthcare companies seeking advanced data insights. However, IQVIA's Research & Development Solutions unit faced some headwinds, including cancellations from large drugmakers re-prioritizing their development pipelines.

Looking ahead, IQVIA reaffirmed its full-year 2025 revenue guidance range of $15.73 billion to $16.13 billion, with the midpoint slightly below Wall Street's expectations of around $16.02 billion. The company's adjusted earnings per share outlook of $11.70 to $12.10 was in line with analysts' estimates of approximately $11.90.

Analysts remain optimistic about IQVIA's prospects, citing the company's strong position in the healthcare data analytics market and its ability to navigate challenges in the clinical research space. The pre-market surge in IQVIA's stock reflects investors' confidence in the company's ability to deliver sustained growth, driven by its technology and analytics capabilities.